Page 3 - Davide Olson News Today

Psychedelic-Like Drug Lacking Hallucinogenic Side Effects Identified with New Sensor Psychedelic-Like Drug Lacking Hallucinogenic Side Effects Identified with New Sensor This is a representative image of cultured dissociated hippocampal neurons transiently expressing psychLight1 and psychLight2. [Chunyang Dong, Calvin Ly, and Joanne Ly at UC Davis] April 28, 2021 Share At the University of California (UC), Davis, psychLight just dropped in to see what condition serotonin dynamics was in. And p...

Share: BOSTON, April 28, 2021 /PRNewswire/ -- Delix Therapeutics, a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, lauded a study published today in the highly-regarded scientific journal Cell by Delix Co-founder and Chief Scientific Officer, Professor David E. Olson, PhD. The paper, co-authored by Olson and collaborator Lin Tian, PhD, both of whom are professors at the University of California, Davis, reveals ...

 E-Mail IMAGE: This is a representative image of cultured dissociated hippocampal neurons transiently expressing psychLight1 and psychLight2. Scale bar, 20 mm. view more  Credit: Calvin Ly Psychedelic drugs have shown promise for treating neuropsychiatric disorders such as depression and posttraumatic stress disorder. However, due to their hallucinatory side effects, some researchers are trying to identify drugs that could offer the benefits of psychedelics without causing hallucinati...

Share this article Share this article BOSTON, April 28, 2021 /PRNewswire/ -- Delix Therapeutics, a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, lauded a study published today in the highly-regarded scientific journal Cell by Delix Co-founder and Chief Scientific Officer, Professor David E. Olson, PhD. The paper, co-authored by Olson and collaborator Lin Tian, PhD, both of whom are professors at the University...

A newly-identified psychedelic-like drug doesnt cause hallucinogenic side effects, scientists reveal. AAZ-A-154 is a previously unstudied molecule that has the potential to act on beneficial pathways in the brain without causing hallucinations.  It stimulates receptors for serotonin – a key hormone sent between nerve cells in our brain that stabilises our mood, well-being and happiness.  In experiments on mice, AAZ-A-154 produced rapid and long-lasting antidepressant-like effects after a si...